Company Description
The statistics are overwhelming: more than 130 people a day die from opioid related drug overdoses. In 2020 in the US alone, 2.7 million people aged 12 or older suffered from Opioid Use Disorder (OUD) and 4.2 million people entered a drug rehabilitation program.While therapy programs and rescue medications are critical, æther THERAPEUTICS is focusing our efforts upstream: preventing addiction and creating a more effective treatment of OUD. Our vision is a world where the devastating effects of opioid addiction are alleviated, leading to: Safer opioid pain therapy without the fear of addictionReversal of opioid addiction Prevention of Neonatal Opioid Withdrawal Syndrome (NOWS) æther THERAPEUTICS is focused on our vision, driven by innovation, while embracing lean operations and engaging with urgency.
Management Team / Advisory Board Bios
Wolfgang Sadee, PhD
Founder & Chief Science Officer
A globally respected thought leader in opioid pharmacology, Dr. Wolfgang Sadee is a founder of æther THERAPEUTICS and serves as Chief Science Officer. Dr. Sadee is also Professor emeritus of Cancer Biology and Genetics, College of Medicine, at the Ohio State University, and Professor emeritus of Bioengineering and Therapeutic Sciences, Colleges of Pharmacy and Medicine, at the University of California San Francisco. Dr. Sadeeʼs prolific research (well over 400 research papers and monographs) has focused on opioid pharmacology, therapeutics, pharmacogenomics, drug response and toxicity.
https://www.linkedin.com/in/wolfgang-sadee-bb39ab10/
John D. Harris
President & Chief Executive Officer
Joining æther THERAPEUTICS in July 2022 as CEO, Mr. Harris brings the critical skillsets, focus and experience to successfully propel the development of ATX-001. Prior to æther, he was the CEO of balboa RESEARCH SMO+, a leading clinical research organization, executing over 50 clinical trials. Mr. Harrisʼ background at large, medium and start-up organizations in the biotech and cell therapy fields provide deep operational, executive and market development savvy.
https://www.linkedin.com/in/john-d-harris-5494156/
Jon S. Saxe
Chairman of the Board
Chairman of the æther THERAPEUTICS Board of Directors, Jon Saxe brings a wealth of experience, having served on over 25 Boards with multiple successful exits. Mr. Saxe was the Vice President, Corporate Development & Licensing, of Hoffmann-LaRoche, CEO of Synergen, President of PDL Biopharma between 1995 and 2000 and served on its board between 1989 and 2010. Currently, Mr. Saxe is the lead director of the investment entity K2X Technology and Life Sciences.
https://www.linkedin.com/in/jon-saxe-96b5385/
Bob Davis, Pharm.D
Senior Scientist, Clinical & Regulatory
With a career spanning over 38 years, Bob Davis has deep experience in developing drugs, biologicals and medical devices as a part of Contract Research Organizations(CROs) and pharmaceuticals. He has been involved in spearheading development of two small molecules and one biological from inception through FDA approval. Dr. Davis led the submission of the first electronically filed NDA to the Endocrine Division in 1999 and has been involved in the creation, monitoring and/or advising of the conduct of over 200 clinical protocols.
https://www.linkedin.com/in/bob-davis-755367b/
John McKew, PhD
Technical Advisor
John McKewʼs tremendous background with the NIH (Chief @ National Center for Advancing Translational Sciences & Director @ Translational Therapeutics) and deep biotech chops (Head of Research @ Tyr Pharma and President of Lumos Pharma) is a tremendous asset to æther THERAPEUTICS.
https://www.linkedin.com/in/johncmckew/
Rick Hawkins
Founder
Rick Hawkins is a 40 year veteran in the biotechnology field and has founded/co-founded three companies that were successfully sold (Pharmaco to PPD; Sensus to Pfizer; Covance to Azko Nobel). In addition to his keen interest in æther THERAPEUTICS, Mr. Hawkins currently runs both ID2 (a pharmaceutical accelerator) and Lumos Pharma, in his role of CEO and Chairman.
https://www.linkedin.com/in/rickhawkins-lumos/
